奥司他韦
医学
随机对照试验
临床试验
解热药
内科学
不利影响
双盲
药品
儿科
疾病
麻醉
药理学
2019年冠状病毒病(COVID-19)
替代医学
传染病(医学专业)
病理
止痛药
安慰剂
作者
Shuo Yang,Yan‐Ming Xie,Lian-Xin Wang
标识
DOI:10.1186/s12906-023-04037-1
摘要
The morbidity of influenza in children increased rapidly in decade. Reduning injection (RDN), a small but fine Chinese herbal formula, has antipyretic, antiviral, anti-inflammatory effects. We intend to evaluate the efficacy and safety of RDN for the influenza in children versus Oseltamivir, explore the possible antiviral mechanism of RDN and provide evidence-based medical evidence for rational clinical drug usage.We design a randomized, double-blind, double-dummy, parallel control of positive drug, multi-centre clinical study. According to the formula of mean superiority test, a total of 240 patients with influenza in children will be randomized 1:1 into the experimental group and control group. The experimental group will take RDN and Oseltamivir phosphate granule simulants and the control group will take Oseltamivir phosphate granule and RDN simulants. Each group will be treated for 5 days. The primary outcome measure is temperature recovery time, and the secondary outcome measures include time when the fever begins to subside, time and degree of disease to alleviate, disappearance rate of individual symptoms and so on. We will measure before enrollment and each 24 h after treatment for comparison.The study is launched to evaluate the efficacy and safety of RDN for the treatment of influenza in children and to provide an alternative option for influenza in children.This study is registered in ClinicalTrials.gov as NCT04183725, registered on 3 December, 2019.
科研通智能强力驱动
Strongly Powered by AbleSci AI